Stapokibart Biosimilar - Research Grade

Product Code: ICH5277

More Information

Species Reactivity: Human

Target: IL4R

Concentration: >1mg/ml

Isotype: Human IgG4 - kappa

Host: CHO Cells

product name H2: Stapokibart Biosimilar - Research Grade

Antibodies against the same target: Dupilumab Biosimilar - Research Grade (ICH5062), Manfidokimab Biosimilar - Research Grade (ICH5256), Rademikibart Biosimilar - Research Grade (ICH5271), Comekibart Biosimilar - Research Grade (ICH5444), Elarekibep Biosimilar - Research Grade (ICH5511)

Sequence: https://www.imgt.org/mAb-DB/

Buffer: ICH3002

UniProt: P24394

Shipping Conditions: Blue ice

background: This product is a research-grade biosimilar of Stapokibart, supplied as an unconjugated, non-therapeutic analog of the originator antibody for research use only. It is not the clinical drug and is not intended for therapeutic or diagnostic use in humans. The molecule is built as a human IgG4-kappa immunoglobulin directed against the interleukin-4 receptor alpha subunit (IL-4Rα, UniProt P24394), reproducing the antigen-binding specificity of the reference product so investigators can study receptor engagement and downstream signalling in controlled experimental systems. Stapokibart itself is an anti-IL-4Rα therapeutic developed for type 2 inflammatory conditions such as atopic dermatitis and

chronic rhinosinusitis with nasal polyps, where it blocks signalling shared by IL-4 and IL-13. As a biosimilar reagent, this material is well suited to binding assays, receptor-blockade and neutralisation studies, and as a reference or control antibody in comparative pharmacology work. It is offered at low endotoxin, in-vivo-compatible quality standards and in bulk milligram-to-gram quantities to support assay development, characterisation, and mechanistic research programs. Interleukin-4 receptor alpha (IL-4Rα, encoded by IL4R; UniProt P24394) is the shared, ligand-binding subunit of the receptors for IL-4 and IL-13, two central drivers of type 2 (Th2) immune responses. IL-4Rα pairs with the common gamma chain to form the type I receptor that responds to IL-4, and with IL-13Rα1 to form the type II receptor that responds to both IL-4 and IL-13. Engagement triggers JAK-STAT signalling, predominantly through STAT6, promoting Th2 differentiation, IgE class switching, goblet cell metaplasia, and eosinophilic inflammation. Because IL-4Rα sits at the convergence point of both cytokines, blocking it simultaneously interrupts the IL-4 and IL-13 axes. This makes IL-4Rα a heavily studied node in allergic and atopic disease biology, including atopic dermatitis, asthma, and chronic rhinosinusitis, and a well-validated target for antibody-mediated pathway inhibition.

Other names: IL-4 receptor subunit alpha, IL-4R subunit alpha, IL-4R-alpha, IL-4RA, Interleukin-4 receptor subunit alpha

Specificity: Detects human IL4R

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >95% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Delivery Time: 4 weeks